Ownership and insider activity for Telix Pharmaceuticals Limited (TLX): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer.
Price
| Price | $9.05 (closing price, November 2, 2026) |
| Market Cap | $3.1B |
| Exchange | NASDAQ |
| Country | AU |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-07 | Smith Darren Charlton | P-Purchase | 2,071 | $20K |
| 2026-05-11 | GILL DAVID N | |||
| 2026-05-11 | Jellison William R | |||
| 2026-05-11 | Rivas Maria | |||
| 2026-04-29 | Behrenbruch Christian | P-Purchase | 33,435 | $497K |
| 2026-04-28 | Behrenbruch Christian | P-Purchase | 34,500 | $500K |
| 2026-03-29 | Smith Darren Charlton | M-Exempt | 1,111 | |
| 2026-03-29 | Smith Darren Charlton | M-Exempt | 1,111 | |
| 2026-03-18 | Cade David Norman | |||
| 2026-03-18 | Cade David Norman | 78,189 | $387K |
Balance Sheet (10y)
| Year | 2000 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.0M | $48.8M | $25.8M | $44.6M | $77.9M | $22.0M | $116.3M | $123.2M | $710.3M | $141.8M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $55,000 | $488,831 | $9.0M | $13.0M | $14.2M | $20.8M | $31.1M | $79.5M | $159.0M | $138.3M |
| Inventory | 0 | 0 | $642,525 | $542,000 | $633,000 | $3.5M | $5.8M | $17.3M | $38.1M | $37.1M |
| Total Current Assets | $3.0M | $49.5M | $35.9M | $58.7M | $93.6M | $47.5M | $173.2M | $224.8M | $918.6M | $330.2M |
| Property, Plant & Equipment | $6.3M | $5,389 | $226,171 | $1.9M | $4.8M | $6.3M | $18.8M | $30.5M | $54.3M | $115.6M |
| Goodwill | 0 | $332,489 | $3.1M | $4.2M | $4.2M | $4.1M | $5.5M | $4.8M | $106.6M | $198.9M |
| Intangible Assets | 0 | $1.2M | $36.3M | $41.9M | $59.2M | $55.7M | $59.0M | $104.8M | $309.5M | $393.7M |
| Total Assets | $9.4M | $51.1M | $76.7M | $102.6M | $157.8M | $109.8M | $255.4M | $398.3M | $1.52B | $1.18B |
| Accounts Payable | $352,000 | $275,844 | $3.2M | $7.0M | $5.8M | $11.9M | $16.8M | $32.8M | $68.7M | $71.6M |
| Short-term Debt | 0 | $345,433 | $1.1M | $469,000 | $264,000 | $19,000 | $636,238 | $964,000 | $19.0M | $13.1M |
| Total Current Liabilities | $352,000 | $1.5M | $8.2M | $10.6M | $20.0M | $38.0M | $85.6M | $157.4M | $330.9M | $231.6M |
| Long-term Debt | 0 | 0 | $596,295 | $292,000 | $95,000 | 0 | $3.3M | $8.2M | $551.8M | $391.8M |
| Total Liabilities | $352,000 | $1.8M | $23.8M | $32.5M | $78.8M | $106.2M | $175.3M | $249.4M | $948.2M | $766.5M |
| Retained Earnings | -$6.1M | -$6.4M | -$20.2M | -$48.1M | -$93.0M | -$173.5M | -$272.8M | -$263.7M | -$213.0M | -$154.5M |
| Total Equity | $9.0M | $49.3M | $52.9M | $70.1M | $79.0M | $2.2M | $80.0M | $148.9M | $568.2M | $415.2M |
| Total Debt | 0 | $345,433 | $1.7M | $2.1M | $2.2M | $2.5M | $10.4M | $17.4M | $581.4M | $467.0M |
| Net Debt | -$3.0M | -$48.4M | -$24.0M | -$42.5M | -$75.7M | -$19.5M | -$105.9M | -$105.8M | -$128.9M | $325.1M |
| Working Capital | $2.7M | $48.1M | $27.6M | $48.1M | $73.7M | $9.6M | $87.7M | $67.4M | $587.7M | $98.6M |
Financial Health
| Debt / Equity | 1.19 |
| Current Ratio | 2.01 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 2.62 |
Profitability
| Return on Equity | 7.24% |
| Return on Invested Capital | -0.61% |
| Return on Assets | 2.40% |
| Gross Margin | 52.14% |
| Operating Margin | -0.78% |
| Net Margin | 3.69% |
Related companies: VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L · RVMD
Explore sector: Healthcare · Biotechnology
More sections of TLX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks